Feb 17 (Reuters) - Alpha Healthcare Acquisition Corp

:

* HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANY CAPABLE OF MANUFACTURING UNIVERSALLY IMPLANTABLE BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, GOING PUBLIC VIA MERGER WITH ALPHA HEALTHCARE ACQUISITION CORP.

* ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION VALUES HUMACYTE AT A PRE-MONEY VALUATION OF $800 MILLION

* ALPHA HEALTHCARE ACQUISITION CORP - FOLLOWING TRANSACTION CLOSING, HUMACYTE IS EXPECTED TO HAVE A MARKET CAPITALIZATION OF $1.1 BILLION

* ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION IS EXPECTED TO PROVIDE UP TO $255 MILLION OF CASH PROCEEDS, INCLUDING A FULLY COMMITTED $175 MILLION PIPE

* ALPHA HEALTHCARE ACQUISITION CORP - AS A RESULT OF OUTSIZED DEMAND, PIPE OFFERING WAS OVERSUBSCRIBED AND UPSIZED

* ALPHA HEALTHCARE ACQUISITION CORP - COMBINED COMPANY EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER SYMBOL "HUMA."

* ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED FRESENIUS MEDICAL CARE, ORBIMED, MONASHEE INVESTMENT MANAGEMENT, ALEXANDRIA VENTURE INVESTMENTS

* ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED UBS O'CONNOR, MORGAN CREEK CAPITAL, AND A NUMBER OF UNNAMED HEALTH CARE FOCUSED FUNDS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))